Pharming says FDA expands Joenja approval to treat APDS in children aged 4-11 weighing at least 27 kg
Reuters2026/09/11 18:00Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- FDA cleared Pharming’s Joenja for APDS in children aged 4-11 weighing at least 27 kg, expanding the U.S. label.
- New 40 mg and 50 mg twice-daily doses are expected to reach the U.S. market in October.
- Joenja was previously authorized in the U.S. for APDS patients aged 12 and older.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609111400OMX_____CNEWS_EN_GNW1001262320_en) on September 11, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
What Will Happen to the Price of Bitcoin If the Fed Raises Interest Rates Next Week?
BitcoinSistemi•2026/09/11 20:36
Impact BioMedical to Effect 1-for-12.62 Reverse Stock Split
MT newswire•2026/09/11 20:32
Peraso holds annual shareholder meeting with 41.62% of voting power represented
Reuters•2026/09/11 20:31
